Medibiofarma

Innovative target-based medicinal chemistry

Enabling T-Cell infiltration in cancer

First-in-class small molecules for Crohn’s disease and neurodegeneration

Vision

To make a real difference to the outlook for patients and their families to become a reference European Biotechnology company with the capabilities to develop desperately needed therapies in complex or untreated diseases

Medibiofarma discovers and develops new chemical entities (NCEs) with clinical proof-of-concept  data in human patients

All activities are carrie out internally or throughpartnerships with contract research organizations, research centres and universities.

Latest News